BeiGene looks to carve out niche in China for tislelizumab

As it looks to roll out what will be at least the sixth marketed PD-1 inhibitor in China, BeiGene hopes the therapy’s differentiated efficacy profile and commercial infrastructure will help the company carve a niche for tislelizumab.

NMPA’s late December approval of the drug made it at least the third

Read the full 498 word article

User Sign In